摘要
通过对现有医学证据的检索,明确人血白蛋白应用于危重患者的临床有效性,为临床合理应用人血白蛋白提供依据。电子检索CNKI、Medline、Cochrane等数据库,收集循证医学证据,包括系统评价和大型随机对照试验,及循证医学研究在临床中的应用等文献。结果表明人血白蛋白不能降低危重患者病死率和并发症的发生率,与晶体液及胶体液相比较,对某些疾病无明显益处。我国应建立人血白蛋白的临床应用指导原则,使临床应用规范化。
We searched medical evidence to identify the clinical efficacy of human serum albumin （HSA） administration in critically ill patients to provide basis for the normalization use of HSA. We searched evidences from CNKI、MEDLINE and Cochrane library, including systematic review, randomized controlled trials and literatures on evidence-based medicine. There was no evidence that human serum albumin reduced the mortality and complication of the critically ill patients. To compare with other colloids and crystalloids, human serum albumin had no advantage obviously to some diseases. We suggested establishing the principle of human serum albumin administration, which will makes the standardization of HSA using.
出处
《医学与哲学（B）》
2008年第4期50-51,73,共3页
Medicine & Philosophy(B)
关键词
人血白蛋白
危重病人
循证医学
随机临床研究
医学评价
human serum albumin, critically ill, evidence- based medicine, randomized controlled trials, medical evalution
